Researchers Search for BRCA1 Treatment Option for Hereditary Breast Cancer
the Cancer Therapy Advisor take:
According to the National Cancer Institute, approximately 12% of women in the United States will develop breast cancer in their lifetime.
In women who inherit a BRCA1 mutation, 55% to 65% will develop breast cancer by the age of 70. Commonwealth Health Research Board awarded a grant to Deborah Kelly, PhD, and Zhi Sheng, PhD, from Virginia Tech Carilion Research Institute to study hereditary breast cancer, which may lead to possible treatment options for those who inherit the harmful BRCA1 genes in Virginia.
Breast cancer related to BRCA1 mutations are linked to poor outcomes, and residents of Virginia have a statistically poorer outcome than the rest of the United States. Dr. Kelly said that BRCA1-related tumors lack HER2 receptors, estrogen, and progesterone, which are drug targets that are effective for other types of breast cancer.
Since no targeted treatments for patients with BRCA1-related tumors exist, the disease is more aggressive and more likely to recur. A healthy BRCA1 gene is a tumor suppressor and produces a protein that assists in repairing damaged cell DNA before mitosis, or cell division.
Researchers at Virginia Tech recently received a grant to investigate hereditary breast cancer.
The grant will fund a two-year project to study the mechanisms behind hereditary breast cancer related to the BRCA1 gene.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed